T-cell receptor on CD4+ T cells recognizing MHC class II–Glatiramer acetate complexes (TCR (CD4+/MHC II-GA))

The T-cell receptor (TCR) on CD4+ T cells that recognizes MHC class II–Glatiramer acetate (Copemyl) complexes is a pivotal mediator in the therapeutic management of relapsing-remitting multiple sclerosis. Glatiramer acetate is a synthetic polymer of four amino acids that mimics myelin basic protein and competes for binding to MHC class II molecules on the surface of antigen-presenting cells (PMID: 12191215). When the TCR on specific CD4+ T cells interacts with these MHC-drug complexes, it triggers a signaling cascade that promotes the differentiation of anti-inflammatory Th2-like regulatory T cells (PMID: 15546724). These drug-specific T cells are capable of crossing the blood-brain barrier, where they encounter myelin antigens and secrete protective cytokines such as IL-4, IL-10, and TGF-beta. This process, known as bystander suppression, reduces the localized inflammatory response and protects the myelin sheath from further autoimmune destruction. Consequently, this TCR-mediated interaction is the primary mechanism by which Glatiramer acetate reduces the frequency of clinical relapses and slows the progression of disability in patients.

Other names

Glatiramer acetate-reactive T-cell receptorCopemyl-reactive T-cell receptorCopaxone-reactive T-cell receptorMHC II-GA complex receptorTCR-CD3 complex (Glatiramer acetate specific)

Glatiramer acetate (Copemyl) acts as an altered peptide ligand that binds to MHC class II molecules on antigen-presenting cells. The resulting MHC-drug complex is recognized by specific T-cell receptors on CD4+ T cells, inducing a phenotypic shift from pro-inflammatory Th1/Th17 cells to anti-inflammatory Th2 regulatory cells. These activated regulatory T cells migrate to the central nervous system and release anti-inflammatory cytokines, suppressing the autoimmune attack on myelin.